1st patient enrolls in Bio2 Technologies cervical spinal fusion trial

Alan Condon -   Print  |

Bio2 Technologies enrolled its first index patient in its Vitrium cervical interbody trial.

Four insights:

1. Pre-clinical studies showed that Vitrium implants are substituted with regenerated bone while demonstrating the strength required for reconstructive surgeries such as spinal fusion.

2. Vitrium uses a bioactive material that provides the strength and porosity to facilitate remodeling throughout the spinal fusion site

3. Bio2 plans to enroll up to 168 participants in the study comparing the Vitrium cervical implant to allograft.

4. COO of Bio2, Janet Krevolin, PhD, hopes to find an optimum outcome of a "total biologic fusion with no foreign material remaining in the disc space."

More articles on devices:
NY hospital earns Center of Excellence in Orthopedic Surgery
Dr. Dominic Thomas Kleinhenz joins spine surgery team at University Orthopedics
US News: 20 best hospitals for neurology and neurosurgery



© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers